Data Citations McCulloch L: Interleukin-1 receptor antagonist treatment in acute ischaemic stroke will not alter systemic markers of anti-microbial defence, [dataset]. C9 in g/ml) – Figure 4 full data excel format.xlsx (concentrations of complement components Factor B and MBL in g/ml) – Figure 5 full data excel format.xlsx (maximum concentrations of noradrenaline in ng/ml) Extended data Edinburgh Data Share: Supplementary Figures: Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. https://doi.org/10.7488/ds/2626 9 This project contains the following extended datain the zip Nutlin carboxylic acid folder SupplementaryData: – Supplementary Figure 1.tif (figure showing maximum concentrations of immunoglobulin) – Supplementary Figure 2.tif (figure showing maximum concentrations of complement components C3b/iC3b, C3, C4, Factor H and Properdin) – Supplementary Figure 3.tif (figure showing minimum concentrations of complement components C1q, C5, C9, C2 and C4b) – Supplementary Figure 4.tif (figure showing minimum concentrations of noradrenaline) – Supplementary Table 1.tif (table of baseline characteristics of stroke patients and stratification of groups) – Supplementary Figure 5.tif (figure showing the percentage of patients reaching minimum circulating concentration Nutlin carboxylic acid of immunoglobulin subsets at each sampling time point) – Supplementary Figure 6.tif (figure showing the percentage of patients reaching minimum circulating concentration of complement components reduced by stroke at each sampling time point) – Supplementary Figure 7.tif (figure showing the percentage of patients reaching maximum circulating concentration of complement components increased by stroke at each sampling time point) – Supplementary Figure 8.tif (figure showing Nutlin carboxylic acid immunoglobulin concentration in IL-1ra and placebo treated patients at individual sampling points after stroke) – Supplementary Figure 9.tif (figure showing alternative pathway complement concentration in IL-1ra and placebo treated patients at individual sampling points after stroke) – Supplementary Figure 10.tif (figure showing classical pathway complement concentration in IL-1ra and placebo treated patients at individual sampling points after stroke) – Supplementary Figure 11.tif (figure showing complement concentration in IL-1ra and placebo treated patients at individual sampling points after stroke) – Data Supplementary Fig 1.xlsx – Data Supplementary Fig 4.xlsx (data underlying Supplementary Figures 1-4) – Data Supplementary Fig 5.xlsx (Supplementary Table 1 in spreadsheet format) – Complement period program data Supplementary numbers 6, 7, 9, 10, 11.xlsx (data underlying supplementary numbers 6, 7, 9 10 and 11) – Immunoglobulin period program data Supplementary numbers 5, 8.xlsx (data underlying supplementary Nutlin carboxylic acid numbers 5 and 8) Data can be found under the conditions of the Creative Commons Attribution 4.0 International permit (CC-BY 4.0). Edition Changes Modified.?Amendments from Nutlin carboxylic acid Edition 1 We are pleased the reviewer recognises the relevance of the study to the near future treatment of heart stroke individuals and thank them for his or her insightful and constructive Rabbit Polyclonal to Cyclin C remarks. We have finished the recommended reanalysis of our data including identifying at which period point optimum and minimal concentrations had been reached in specific mediators and repeated procedures analysis of examples at individual period points compared to admission. Needlessly to say, these data demonstrate the high variability in specific individual kinetics and concur that evaluating minimal or maximal concentrations in this short time home window (a week) can enable finding of early reactions to heart stroke that are biologically significant but where peaks/ troughs could be happening at somewhat different period point in specific patients. Significantly, no variations in individual kinetics were obvious in placebo and IL-1ra treated organizations further confirming the main element results that IL-1Ra does not have any significant additional influence on these mediators in addition to the consequences of heart stroke. Additionally, we’ve added.